Drugs / autologous HSCs
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06514898 Background | May 2025 → Sep 2027 expected | medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | University of Florida | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous HSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06514898 ↗ |
| Modality | Cell therapy | “autologous HSCs” NCT06514898 ↗ |
| Route | Intravenous | “single intravenous infusion of autologous HSCs” NCT06514898 ↗ |